https://www.prnewswire.com/news-releases/aeterna-zentaris-to-raise-us78-million-in-registered-direct-offering-216914101.html
Aeterna Zentaris to Raise US$7.8 Million in Registered Direct Offering
/PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") announced today that it has received commitments from institutional investors...
https://sheffield.ac.uk/smph/news/aeterna-zentaris-announces-notice-allowance-us-patent-covering-aezs-150-potential-treatment-chronic
Aeterna Zentaris Announces Notice of Allowance for U.S. Patent Covering AEZS-150 for the Potential...
Aeterna Zentaris Inc. today announced that its licensor, The University of Sheffield, has received a notice of allowance from the U.S. Patent and Trademark...
https://www.businesswire.com/news/home/20230315005846/en/Pharmanovia-Enters-Into-an-Exclusive-Licensing-Agreement-With-Aeterna-Zentaris-for-the-First-and-Only-Orally-Administered-Approved-Medicine-for-the-Diagnosis-of-Growth-Hormone-Deficiency-in-Adults
Pharmanovia Enters Into an Exclusive Licensing Agreement With Aeterna Zentaris for the First and...
Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines,...
https://www.newswire.ca/news-releases/aeterna-zentaris-data-safety-monitoring-board-recommends-continuation-of-phase-3-study-of-zoptarelin-doxorubicin-in-advanced-endometrial-cancer-517493411.html
Aeterna Zentaris: Data Safety Monitoring Board Recommends Continuation of Phase 3 Study of...
/CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that the independent Data Safety Monitoring Board ("DSMB") for...
data safety